Pixantrone (Pixuvri®)

Assessment Status Rapid Review Complete
Drug Pixantrone
Brand Pixuvri®
Indication Is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL).
Assessment Process
Rapid review commissioned 10/02/2015
Rapid review completed 20/03/2015
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended